Complications and Outcomes of Impella Treatment in Cardiogenic Shock Patients With and Without Acute Myocardial Infarction

• DOI: 10.1161/jaha.123.030819
• Publication Date: 2023-08-30T09:28:25Z
• Authors: Yuichi Saito; Kazuya Tateishi; Koichi Toda; Goro Matsumiya; Yoshio Kobayashi
• Keywords: Impella; Myocardial infarction complications; Clinical endpoint

Background In patients with cardiogenic shock (CS), acute myocardial infarction (AMI) is the most common cause, and a percutaneous microaxial ventricular assist device (Impella, Abiomed, Danvers, MA) choice for temporary mechanical circulatory support. However, data are limited on complications outcomes of Impella treatment in CS without AMI. Methods Results Using nationwide prospective registry Japan, we included total 2047 whom devices were successfully placed between February 2020 December 2021. Patients divided into 2 groups according to primary indication use: AMI versus non-AMI. The end point was composite in-hospital all-cause death major complications. Of patients, indicated 1337 (65.3%). group AMI, myocarditis leading cause CS. AMI-CS older more likely have cardiovascular risk factors than those non-AMI-CS. rates mortality (46.0% 43.9%, P=0.38) (35.2% 34.7%, P=0.85) similar groups. Overall, multivariable analysis identified age, higher body mass index, previous transient ischemic attack or stroke, out-of-hospital cardiac arrest, 5.0 as significantly associated point. Conclusions use related clinical high complication rates. Further studies needed identify who may benefit from Registration URL: https://www.umin.ac.jp/english. Identifier: UMIN000033603.